Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Science Clips
COVID-10 GPH

Last data update: Mar 10, 2025. (Total: 48852 publications since 2009)
(Author names in bold with hyperlink are CDC authors)
Filtered By:
Order By:
Records 1-1 (of 1 Records)
Query Trace: Chickery S [original query]
Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged ≥18 years - VISION and IVY Networks, September 2024-January 2025
Link-Gelles R , Chickery S , Webber A , Ong TC , Rowley EAK , DeSilva MB , Dascomb K , Irving SA , Klein NP , Grannis SJ , Barron MA , Reese SE , McEvoy C , Sheffield T , Naleway AL , Zerbo O , Rogerson C , Self WH , Zhu Y , Lauring AS , Martin ET , Peltan ID , Ginde AA , Mohr NM , Gibbs KW , Hager DN , Prekker ME , Mohamed A , Johnson N , Steingrub JS , Khan A , Felzer JR , Duggal A , Wilson JG , Qadir N , Mallow C , Kwon JH , Columbus C , Vaughn IA , Safdar B , Mosier JM , Harris ES , Chappell JD , Halasa N , Johnson C , Natarajan K , Lewis NM , Ellington S , Reeves EL , DeCuir J , McMorrow M , Paden CR , Payne AB , Dawood FS , Surie D .
MMWR Morb Mortal Wkly Rep 2025 74 (6) 73-82 New Added Today

COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.
TOP